SEC Company Response from AIBOTICS, INC. (AIBT) (CIK 0001763329) (AIBT) — Jan 14, 2022
AIBOTICS, INC. (AIBT) (CIK 0001763329)
Date: Jan. 14, 2022 · CIK: 0001763329 · Accession: 0001096906-22-000128
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-11770
Letter
United States Securities Division of Corporation Finance Office of Trade & Services Form 1-A Filed January 6, 2022 File No. 024-11770
Re: Mycotopia Therapies, Inc.
Dear Mr. Lichtenfels:
Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), Mycotopia Therapies, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Tuesday, January 18, 2022, or as soon thereafter as is practicable.
We understand that the Commission has completed its review and has no further comments.
The Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further acknowledges that:
·Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
·The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its responsibility for the adequacy and accuracy of the disclosures in the filing; and
·The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
If you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.
Thank you in advance for your assistance.
Very Truly Yours,
MYCOTOPIA THERAPIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
January 14, 2022
United States Securities
and Exchange Commission
Division of Corporation Finance
Office of Trade & Services
Attn: Ryan Lichtenfels
Washington, D.C. 20549
Re: Mycotopia Therapies, Inc.
Form 1-A
Filed January 6, 2022
File No. 024-11770
Dear Mr. Lichtenfels:
Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), Mycotopia Therapies, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Tuesday, January 18, 2022, or as soon thereafter as is practicable.
We understand that the Commission has completed its review and has no further comments.
The Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further acknowledges that:
·Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
·The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its responsibility for the adequacy and accuracy of the disclosures in the filing; and
·The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
If you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.
Thank you in advance for your assistance.
Very Truly Yours,
MYCOTOPIA THERAPIES, INC.
By:/s/ Ben Kaplan
Ben Kaplan, CEO